PRESSURE BIOSCIENCES, INC. (OTCMKTS:PBIO) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.

On April 10, 2017, Mr. Joseph L. Damasio Jr. joined Pressure
BioSciences, Inc. (the Company) as its Vice President of Finance
and Chief Financial Officer (CFO).

Mr. Damasio, age 42, has 20 years of finance and accounting
experience, most recently as Finance Director of Nelipak
Corporation. Prior to Nelipak Corporation, Mr. Damasio held
various financial positions at CP Bourg, IQE, and Kopin
Corporation. Prior to Kopin Corporation, Mr. Damasio was employed
for 6 years by the Company, first as Controller and later as Vice
President of Finance Administration. Mr. Damasio became a CPA in
2003, and earned a B.S.B.A. in accounting from the University of
Massachusetts and an MBA from Boston College.

Family Relationships

There are no family relationships between Mr. Damasio and any
other executive officer or member of the board of directors of
the Company.

Related Party Transactions

There are no related party transactions with regard to Mr.
Damasio reportable under Item 404(a) of Regulation S-K except
that, since January 1, 2016, the Company has paid Mr. Damasio
$44,000 for his services as a financial consultant.

Material Plans, Contracts, or Arrangements

In connection with Mr. Damasios appointment as the Companys Vice
President of Finance and CFO, Mr. Damasio will be paid an annual
salary of $170,000. After one year of service, if Mr. Damasio is
terminated without cause, he will be entitled to receive
severance in an amount equal to one year base salary, plus
medical benefits. Effective immediately on date of hire, if Mr.
Damasio is terminated due to change of control, he will be
entitled to receive severance in an amount equal to one year base
salary, plus medical benefits.

About PRESSURE BIOSCIENCES, INC. (OTCMKTS:PBIO)

Pressure BioSciences, Inc. is focused on solving the problems inherent in biological sample preparation. The Company has developed and patented a technology platform that can control the sample preparation process. This process, called pressure cycling technology (PCT), uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels, such as approximately 35,000 pounds per square inch (psi) or greater to control the actions of molecules in biological samples, such as cells and tissues from human, animal, plant and microbial sources. Its laboratory instrument, the Barocycler, and its consumables product line, which include its Pressure Used to Lyse Samples for Extraction (PULSE) tubes, and other processing tubes, and application specific kits, such as consumable products and reagents, together make up its PCT Sample Preparation System (PCT SPS). The Company is also the distributor for the Constant Systems cell disruption equipment, parts, and consumables.

PRESSURE BIOSCIENCES, INC. (OTCMKTS:PBIO) Recent Trading Information

PRESSURE BIOSCIENCES, INC. (OTCMKTS:PBIO) closed its last trading session down -0.010 at 0.326 with 7,000 shares trading hands.